David Novack, President & COO of Dynavax Technologies Corporation (NASDAQ:DVAX), exercised 114,000 stock options and immediately sold the resulting shares for a transaction value of approximately $1.8 million, according to the SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 114,000 Transaction value $1.8 million Post-transaction shares (direct) 63,344 Post-transaction value (direct ownership) ~$989,433.28 Transaction value based on SEC Form 4 weighted av ...

Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the stocks Jim Cramer recently looked at. When a caller noted that they bought the stock three years ago for around $12, Cramer remarked: “Congratulations. You know that one’s done. They got that nice bid from Sanofi. I’m going to actually go out there and talk to them about that… Well played, my friend.” Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels Dynavax Technologies Corporation (NASDAQ:DVAX) is a bio ...

Click here for more info https://monteverdelaw.com/case/dynavax-technologies-corporation/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with ...

The updated release reads: DYNAVAX INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF DYNAVAX TECHNOLOGIES CORPORATION - DVAX NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Please replace the release issued December 29, 2025 with the following corrected version due to multiple revisions. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok ...

Core Viewpoint - The proposed sale of Dynavax Technologies Corporation to Sanofi is under investigation by former Louisiana Attorney General Charles C. Foti, Jr. and the law firm Kahn Swick & Foti, LLC to assess the fairness of the transaction and the process leading to it [1] Group 1: Transaction Details - Shareholders of Dynavax Technologies Corporation are set to receive $221.50 in cash for each share they own as part of the proposed sale to Sanofi [1]

Core Viewpoint - Sanofi is set to acquire Dynavax for approximately $2.2 billion, enhancing its vaccine portfolio amid changing vaccine policies in the US [1][4] Group 1: Acquisition Details - The acquisition price is $15.50 per share in cash, with the deal expected to close in the first quarter of 2026 [1] - Sanofi will gain Dynavax's hepatitis B vaccine HEPLISAV-B, which was approved in the US in 2017 and in Europe in 2021 [2] - Sanofi currently lacks a hepatitis B vaccine in its portfolio, having previously partnered with MSD for a vaccine that is now solely commercialized by MSD [2] Group 2: Product and Market Insights - HEPLISAV-B is administered in a two-dose regimen within one month, contrasting with competitors GSK's Engerix-B and MSD's Recombivax HB, which require three doses over six months [3] - HEPLISAV-B generated sales of $268.4 million in 2024, with Dynavax projecting net product revenue of $305 million to $325 million for 2025 [3] - GlobalData forecasts that HEPLISAV-B will achieve annual sales of $677 million by 2031 [3] Group 3: Industry Context and Regulatory Changes - The acquisition comes amid significant regulatory changes, as the CDC has altered its guidance, no longer recommending hepatitis B vaccination for all US newborns, leading to volatility in the vaccine sector [4] - Analyst Matt Phipps noted that the deal value is slightly below the net present value for HEPLISAV-B, but the acquisition aligns with addressing regulatory concerns and investor expectations for value creation [4] Group 4: Future Prospects - Dynavax's pipeline includes a shingles vaccine candidate, Z-1018, currently in Phase I/II trials, which has shown comparable efficacy to GSK's Shingrix while having fewer adverse reactions [5] - The shingles market is significant, with Shingrix generating £3.4 billion globally for GSK in 2024, indicating the potential market size for Z-1018 [6]

Group 1 - Sanofi has announced a definitive agreement to acquire Dynavax Technologies Corporation for $15.50 per share, totaling approximately $2.2 billion in equity value [1][3] - The acquisition aligns with Sanofi's strategy to expand its presence in adult immunization, particularly through Dynavax's hepatitis B vaccine, HEPLISAV-B, which is the only two-dose adult hepatitis B vaccine approved in the US [2][3] - The deal has been unanimously approved by Dynavax's board and is expected to close in the first quarter of 2026, with no impact on Sanofi's financial guidance for 2025 [3] Group 2 - Analysts have a positive outlook on Sanofi, with a 12-month price target reflecting more than 26% upside from the current level, and a recent Hold rating with a price target of $57 from TD Cowen [4]

Market Overview - Asian shares exhibited mixed performance amid thin holiday trading, with most markets closed for Christmas. The Nikkei 225 in Tokyo increased by 0.1% to 50,407.79, marking a nearly 30% gain for the year [1] - The Shanghai Composite index in mainland China rose by 0.5% to 3,959.62, while Hong Kong's exchange was closed [1] Central Bank Actions - The People's Bank of China (PBOC) reassured investors by committing to ensure adequate money supply to support financing, economic growth, and inflation targets. The PBOC maintained its key short-term lending rates earlier in the week [2] US Market Performance - The S&P 500 index increased by 0.3% to 6,932.05, while the Dow Jones Industrial Average rose by 0.6% to 48,731.16, and the Nasdaq composite added 0.2% to 23,613.31 [3] - The S&P 500 has gained over 17% this year, driven by investor optimism regarding the Trump administration's deregulatory policies and the potential of artificial intelligence to enhance profits across various sectors [5] Economic Indicators - The US economy experienced a robust growth rate of 4.3% annually in Q3, the fastest in two years, primarily fueled by consumer spending despite high inflation [7] - Jobless claims in the US decreased by 10,000 to 214,000 for the week ending December 20, remaining below the forecast of 232,000 new applications, indicating a still healthy labor market [8] Company News - Dynavax Technologies' shares surged by 38.2% following Sanofi's announcement of acquiring the company for $2.2 billion, which will enhance Sanofi's vaccine portfolio [9] - Novo Nordisk's shares rose by 1.8% after receiving US regulatory approval for a pill version of its weight loss drug Wegovy, although the company’s shares are down nearly 40% this year due to increased competition from Eli Lilly, whose shares have increased by 40% this year [10]

Market Overview - U.S. stock futures declined on Friday following a higher close on Wednesday, with major benchmark indices showing a decrease [1][2] - The Dow Jones futures fell by 0.12%, S&P 500 by 0.06%, Nasdaq 100 by 0.06%, and Russell 2000 by 0.27% [2] - The SPDR S&P 500 ETF Trust (SPY) decreased by 0.029% to $690.18, while Invesco QQQ Trust ETF (QQQ) fell by 0.014% to $623.84 in premarket trading [2] Economic Data - U.S. initial jobless claims dropped by 10,000 to 214,000 for the week ending Dec. 20, better than market expectations of 223,000 [1] - The 10-year Treasury bond yield was at 4.15%, and the two-year bond yield was at 3.51% [2] - The CME Group's FedWatch tool indicates an 84.5% probability that the Federal Reserve will keep interest rates unchanged in January [2] Company Highlights - Dynavax Technologies (NASDAQ:DVAX) shares surged by 38.19% following Sanofi's announcement to acquire the vaccines company [5] - Davis Commodities Ltd. (NASDAQ:DTCK) reported revenue of $95 million for the six months ending June 30, a 42.1% increase from $66.9 million a year earlier, leading to a 7.19% rise in its shares [4] - Nvidia Corp. (NASDAQ:NVDA) shares rose by 0.58% after announcing a non-exclusive licensing agreement with AI chip startup Groq [5] - Sobr Safe Inc. (NASDAQ:SOBR) shares dropped by 15.61% after announcing a private placement of 1.29 million shares at $1.55 per share [5][6] - Biohaven Ltd. (NYSE:BHVN) shares fell by 14.06% after its Phase 2 study of BHV-7000 in major depressive disorder failed to meet its primary endpoint [13] Analyst Insights - University of Michigan economist Justin Wolfers criticized the media's focus on record stock numbers, stating that U.S. markets are up 18% but lag behind global markets, which have risen by 30% [9][10] - Wolfers highlighted a disconnect between GDP growth of over 4% and a more modest Gross Domestic Income (GDI) growth of 2.4%, suggesting potential job creation stagnation [10]

Market Outlook - The market experienced a phenomenal year in 2025, with the S&P 500 achieving 41 record high closes and a total return of approximately 18% [2] - The bull market reached its 3-year anniversary, and expectations for 2026 include another bull market year with increased volatility and double-digit growth [2] - Key sectors expected to perform well include AI, AI infrastructure, aerospace and defense, biotech, and energy companies, driven by increased capital expenditure over the past two years [2] Diversification Trends - Analysts believe 2026 will emphasize diversification, with the influence of the "Mag Seven" on the S&P 500 weakening [3] - The contribution of the "Mag Seven" to total returns has decreased from 62% two years ago to around 44% for 2025 [3] - Earnings expansion and increased spending are expected to drive double-digit growth, while valuation multiples are anticipated to remain stable [3] Affordable Stocks Analysis - A list of the 15 Best Affordable Stocks was curated using various financial databases, focusing on stocks trading below a forward P/E of 15 with expected upside of over 25% [6] - Hedge fund sentiment was also considered, as imitating top stock picks from hedge funds has historically outperformed the market [7] Company Highlights - **Sanofi (NASDAQ:SNY)**: - Forward P/E Ratio: 10.61, with a 12-month analyst upside potential of 26.14% [8][9] - Recently announced acquisition of Dynavax Technologies for $2.2 billion, enhancing its adult immunization portfolio [9][11] - The acquisition is expected to close in Q1 2026 and will not impact financial guidance for 2025 [11][12] - **PVH Corp. (NYSE:PVH)**: - Forward P/E Ratio: 6.32, with a 12-month analyst upside potential of 30.61% [13] - Experienced a decline of over 21% since its fiscal Q3 2025 earnings release, yet analysts maintain a positive outlook [13] - Fiscal Q3 2025 revenue grew by 1.74% year-over-year to $2.29 billion, exceeding expectations [15] - EPS of $2.83 also surpassed expectations, driven by the execution of the PVH+ plan and growth in key categories [15][16]